Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (11) , 1091-1102
- https://doi.org/10.2165/00019053-200119110-00003
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Cost-Utility Analysis of Chemotherapy Using Paclitaxel, Docetaxel, or Vinorelbine for Patients With Anthracycline-Resistant Breast CancerJournal of Clinical Oncology, 1999
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupEuropean Journal Of Cancer, 1999
- The economic advantages of response in the treatment of advanced breast cancerJournal of Medical Economics, 1999
- Paclitaxel in anthracycline-treated breast cancer patients.Oncology Reports, 1998
- A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast CancerPharmacoEconomics, 1996
- A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclinesEuropean Journal Of Cancer, 1996
- A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast CancerPharmacoEconomics, 1996
- Utility approach to measuring health-related quality of lifeJournal of Chronic Diseases, 1987
- Reporting results of cancer treatmentCancer, 1981